Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

G1 Therapeutics Inc.

http://www.g1therapeutics.com/

Latest From G1 Therapeutics Inc.

Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug

Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.

Deals Business Strategies

EQRx Reveals Two New Assets For Low-Cost Drug Pipeline

The start-up launched in January with $200m to develop lower-priced drugs against known targets. Now it has licensed a CDK4/6 inhibitor from G1 Therapeutics and an EGFR inhibitor from Hansoh.

Deals Business Strategies

G1 Believes Boehringer Is Better Bet To Sell Trilaciclib

G1 Therapeutics had been talking about marketing its recently filed myelosuppression therapy for small cell lung cancer on its own. However a deal with Boehringer represents an alternative "capital efficient launch structure."

Cancer Deals

Asia Deal Watch: Betta Will Bring Two Agenus Oncology Candidates To Its Market Area

Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.

Deals Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register